Turnstone Biologics (NASDAQ:TSBX) Shares Down 9.6%

Turnstone Biologics Corp. (NASDAQ:TSBXGet Free Report) shares traded down 9.6% during trading on Wednesday . The company traded as low as $2.59 and last traded at $2.63. 65,858 shares traded hands during trading, a decline of 64% from the average session volume of 184,698 shares. The stock had previously closed at $2.91.

Turnstone Biologics Stock Down 9.6 %

The business has a fifty day moving average of $2.44.

Turnstone Biologics (NASDAQ:TSBXGet Free Report) last issued its quarterly earnings data on Thursday, November 9th. The company reported ($1.00) EPS for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.33). As a group, equities analysts anticipate that Turnstone Biologics Corp. will post -3.45 EPS for the current year.

Hedge Funds Weigh In On Turnstone Biologics

Several institutional investors have recently modified their holdings of the business. Vanguard Group Inc. bought a new position in shares of Turnstone Biologics in the third quarter valued at approximately $428,000. Citigroup Inc. bought a new position in shares of Turnstone Biologics in the third quarter valued at approximately $30,000. Sectoral Asset Management Inc. bought a new position in shares of Turnstone Biologics in the third quarter valued at approximately $2,040,000. Eventide Asset Management LLC purchased a new position in Turnstone Biologics in the third quarter valued at approximately $2,791,000. Finally, Northern Trust Corp purchased a new position in Turnstone Biologics in the third quarter valued at approximately $228,000. 46.44% of the stock is owned by institutional investors.

Turnstone Biologics Company Profile

(Get Free Report)

Turnstone Biologics Corp., a clinical stage biotechnology company, focuses on developing medicines to treat and cure patients with solid tumors. The company's lead product includes TIDAL-01 that is in Phase 1 clinical trials for the treatment of breast cancer, colorectal cancer, and uveal melanoma, as well as an investigator sponsored trial to treat cutaneous and non-cutaneous melanomas.

Read More

Receive News & Ratings for Turnstone Biologics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Turnstone Biologics and related companies with MarketBeat.com's FREE daily email newsletter.